Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences
about
Low circulating levels of the mitochondrial-peptide hormone SHLP2: novel biomarker for prostate cancer risk.Metabesity and urological cancers.Coffee Intake Decreases Risk of Postmenopausal Breast Cancer: A Dose-Response Meta-Analysis on Prospective Cohort Studies.Low-dose statin treatment increases prostate cancer aggressiveness.Association of Ozone with 5-Fluorouracil and Cisplatin in Regulation of Human Colon Cancer Cell Viability: In Vitro Anti-Inflammatory Properties of Ozone in Colon Cancer Cells Exposed to Lipopolysaccharides.Gendermetrics of cancer research: results from a global analysis on prostate cancer.
P2860
Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Metabolic syndrome, endocrine ...... d pathophysiological evidences
@ast
Metabolic syndrome, endocrine ...... d pathophysiological evidences
@en
type
label
Metabolic syndrome, endocrine ...... d pathophysiological evidences
@ast
Metabolic syndrome, endocrine ...... d pathophysiological evidences
@en
prefLabel
Metabolic syndrome, endocrine ...... d pathophysiological evidences
@ast
Metabolic syndrome, endocrine ...... d pathophysiological evidences
@en
P2093
P2860
P50
P356
P1433
P1476
Metabolic syndrome, endocrine ...... d pathophysiological evidences
@en
P2093
Carla Cavaliere
Carmine D'Aniello
Daniela Vanacore
Elvira Lamantia
Flavia Nocerino
Francesca Cappuccio
Francesco De Falco
Gabriella Malzone
Gennaro Ciliberto
Gianluca Ametrano
P2860
P304
30606-30616
P356
10.18632/ONCOTARGET.16725
P407
P50
P577
2017-05-01T00:00:00Z